CJC-1295 with DAC Safety Profile: Preclinical Tolerability and Adverse Effect Research
Last Updated: May 18, 2026 | Author: Palmetto Peptides Research Team
DISCLAIMER: This article is for educational and scientific research reference purposes only. All compounds discussed are not approved by the FDA for use in humans or animals. All data discussed here reflects preclinical animal research or laboratory use. Palmetto Peptides sells these compounds exclusively for in vitro and preclinical laboratory research. Nothing in this article constitutes medical advice.
Preclinical safety data for CJC-1295 with DAC indicates a favorable tolerability profile across multiple animal model studies, with no dose-limiting toxicity observed at pharmacologically relevant concentrations in rodent and primate models. The drug affinity complex (DAC) modification that distinguishes CJC-1295 from its non-DAC counterpart significantly extends plasma half-life and alters the compound's interaction with albumin — a structural change that carries its own set of tolerability implications researchers must understand before designing experiments.
This review synthesizes available preclinical tolerability data, catalogues observed adverse effects from animal studies, and frames safety parameters relevant to controlled laboratory research settings. Bacteriostatic water is the standard reconstitution vehicle used in these studies, and preparation quality remains a key variable in minimizing confounding injection-site effects.
What is CJC-1295 with DAC? A Brief Structural Overview
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically engineered to resist proteolytic degradation. The full name of the DAC form is CJC-1295 with Drug Affinity Complex, where the DAC moiety is a lysine-maleimidoproprionic acid linker that covalently binds to serum albumin following injection. This albumin binding is the mechanistic basis for the dramatically extended half-life compared to endogenous GHRH (minutes) or CJC-1295 without DAC (roughly 30 minutes post-injection).
The molecular weight of CJC-1295 with DAC is approximately 3647.3 Da. Its sequence is based on the first 29 amino acids of GHRH(1-44), with four substitutions at positions 2, 8, 15, and 27 that prevent DPP-IV enzyme cleavage. The DAC moiety is attached at a C-terminal lysine.
Why the DAC Modification Matters for Safety Research
The albumin-binding mechanism creates a depot effect in plasma. Instead of rapid clearance, CJC-1295 with DAC maintains measurable plasma concentrations over 7-14 days in rodent studies. This prolonged exposure window changes how researchers must think about cumulative dose effects, washout periods, and the interpretation of adverse event timelines. An effect observed on day 5 post-injection may reflect initial dose pharmacology, continued peptide activity, or downstream hormonal cascades — all three require different experimental controls.
Preclinical Dosing Ranges Used in Published Research
Published animal studies have used a range of dosing paradigms. The most frequently cited rodent studies use single subcutaneous doses between 30 mcg/kg and 300 mcg/kg, with repeat-dose protocols typically using weekly injections over 4-6 week observation periods. Primate studies are limited in number but have used doses in the 3-10 mcg/kg range.
| Species | Route | Dose Range | Observation Period | Primary Endpoints |
|---|---|---|---|---|
| Sprague-Dawley rat | Subcutaneous | 30-300 mcg/kg | Single dose + 14-day | GH pulse, IGF-1, body weight |
| Wistar rat | Subcutaneous | 100-500 mcg/kg | 4-6 weeks, weekly | Organ weight, histology, CBC |
| C57BL/6 mouse | Subcutaneous | 50-200 mcg/kg | 8 weeks, twice weekly | Body composition, IGF-1, glucose |
| Rhesus macaque | Subcutaneous | 3-10 mcg/kg | Single dose | GH kinetics, pharmacokinetics |
| Beagle dog | Subcutaneous | 10-50 mcg/kg | Single dose + 7-day | GH pulse amplitude, cortisol |
No published preclinical study has reported a lethal dose (LD50) for CJC-1295 with DAC. The absence of frank toxicity at doses far exceeding pharmacologically active thresholds is a consistent finding across species, though researchers should note this does not imply absence of biologically meaningful perturbation at the hormonal level.
Observed Adverse Effects in Animal Models
Injection Site Reactions
The most consistently reported finding across rodent studies is transient injection-site reactions. These manifest as focal erythema, mild induration, or subcutaneous nodule formation at the injection site, typically resolving within 24-72 hours. The frequency and severity of these reactions correlate with reconstitution vehicle, injection volume, and peptide concentration. Studies using correctly prepared bacteriostatic water at physiological pH report fewer and milder injection-site findings compared to those using water for injection or saline with osmolality mismatches.
Histological examination of injection sites in some rat studies has shown mild inflammatory infiltrate (predominantly mononuclear cells) in a subset of animals at higher doses. This finding is consistent with the known irritant potential of peptide aggregates and is not unique to CJC-1295 with DAC among GHRH analogs.
Hormonal and Metabolic Effects
The downstream hormonal effects of CJC-1295 with DAC represent the most biologically significant category of findings in preclinical safety studies. Because the compound stimulates pituitary GH secretion over an extended period, sustained elevation of circulating IGF-1 is a predictable outcome. In long-duration rat studies (8+ weeks), this persistent IGF-1 elevation has been associated with:
- Mild organomegaly (spleen, kidney, heart) at high doses (300+ mcg/kg in rats)
- Transient alterations in fasting glucose homeostasis in obese mouse models
- Changes in lean mass and fat mass ratios consistent with GH axis activation
- Elevation of markers associated with cellular proliferative signaling in some tissue panels
None of these findings have been characterized as pathological in the formal toxicological sense at doses used in standard research protocols. The organomegaly observed at supratherapeutic rodent doses is dose-dependent and reversible following cessation of dosing, based on available recovery-phase histology data.
Cardiovascular Parameters
Limited cardiovascular safety data exists for CJC-1295 with DAC specifically. Studies measuring blood pressure and heart rate in conscious rodents have not identified significant hemodynamic perturbation at single pharmacological doses. One published study examining weekly dosing over six weeks in rats found no significant change in echocardiographic left ventricular dimensions relative to vehicle-treated controls, though this study used a relatively low dose range (30-100 mcg/kg).
Researchers examining cardiovascular endpoints should note that GH axis activation can influence cardiac remodeling over extended timelines, particularly in the context of underlying metabolic disease models. Appropriate vehicle-matched controls are essential for interpreting any cardiovascular data from long-duration experiments.
Immunological Findings
The DAC modification theoretically introduces a hapten-like antigen to albumin. Preclinical immunogenicity assessment has been reported in a small number of studies, with mixed findings. One rat study examining repeat-dose immunogenicity (weekly injections for 12 weeks) found low-titer anti-peptide antibodies in a minority of animals that received the highest dose tested (500 mcg/kg weekly). No systemic hypersensitivity reactions, anaphylaxis, or immune-complex deposition was observed in any published preclinical study.
Routine complete blood count (CBC) monitoring in repeat-dose rat studies has not revealed consistent hematological changes attributable to CJC-1295 with DAC treatment at pharmacological doses. Differential white cell counts, platelet counts, and hemoglobin values have remained within laboratory reference ranges in available published data.
Hepatic and Renal Safety Markers
Standard hepatic safety markers (ALT, AST, ALP, total bilirubin) and renal markers (BUN, creatinine) have been assessed in repeat-dose rodent studies. No dose-dependent elevation of hepatic enzymes has been reported across available literature. Renal markers have similarly remained stable, including in studies using obese or metabolically compromised animal models where baseline renal function may be modestly impaired.
This finding is not unexpected given that peptide clearance for CJC-1295 with DAC occurs primarily through enzymatic degradation and renal filtration of smaller fragments rather than hepatic first-pass metabolism.
Comparison: CJC-1295 with DAC vs. CJC-1295 without DAC — Safety Profile Differences
| Parameter | CJC-1295 with DAC | CJC-1295 without DAC |
|---|---|---|
| Plasma half-life (rat) | ~6-8 days | ~30 minutes |
| Injection site reactions | Mild, transient in subset | Minimal reported |
| GH pulse pattern | Sustained elevation, blunted pulsatility | Acute pulse preserved |
| IGF-1 elevation duration | 7-14 days per dose | Hours per dose |
| Immunogenicity potential | Low; hapten concern theoretical | Very low |
| Organomegaly risk (supratherapeutic) | Reported at high doses, reversible | Not reported in published data |
| Washout period needed | Minimum 2-3 weeks recommended | 24-48 hours adequate |
| Dosing frequency for sustained effect | Once weekly in rodents | Daily or twice daily |
Key Safety Parameters for Experimental Design
Dose Selection
Researchers designing CJC-1295 with DAC studies should establish both a no-observed-adverse-effect level (NOAEL) reference and a pharmacologically active dose based on published IGF-1 response data. In Sprague-Dawley rats, a dose of 100 mcg/kg subcutaneous weekly consistently produces measurable IGF-1 elevation without evidence of adverse findings. Doses of 300 mcg/kg and above in rodents enter a range where subclinical organomegaly becomes a more frequent incidental finding, though this threshold is substantially higher in larger species.
Washout and Recovery Periods
Given the extended half-life created by the DAC modification, recovery phases in any toxicology study should account for at least 3-4 half-lives of clearance. In rats, a minimum 3-4 week washout before terminal assessments in recovery groups provides adequate time for hormonal normalization based on available pharmacokinetic data.
Control Group Design
Vehicle controls must use the same reconstitution approach as treatment groups. Bacteriostatic water matched for volume and injection site is the standard. Some studies have noted that the DAC modification itself can produce minor injection site responses independent of the peptide backbone, making vehicle-only controls essential for accurate attribution of observed findings.
Monitoring Recommendations from Published Studies
- Body weight at least weekly throughout dosing period
- Fasting IGF-1 measurement as primary pharmacodynamic marker
- CBC and serum chemistry at mid-point and study end for repeat-dose studies beyond 4 weeks
- Organ weight and gross pathology at terminal necropsy
- Injection site gross evaluation at each dosing visit
- Histopathology of injection sites and major organs in high-dose groups
Gaps in the Preclinical Safety Literature
Several safety parameters remain incompletely characterized for CJC-1295 with DAC in preclinical models. Formal reproductive and developmental toxicity studies have not been published. Carcinogenicity data is absent, though sustained IGF-1 elevation is a recognized consideration in the broader GH axis literature. Long-duration studies (beyond 12 weeks) in any species are not represented in the peer-reviewed literature as of this writing. These gaps are relevant context for researchers designing longer-duration experiments or those using disease models with altered proliferative signaling.
Reconstitution Quality and Tolerability
A practical but often underappreciated variable in preclinical peptide research is reconstitution quality. CJC-1295 with DAC is typically supplied as a lyophilized powder and requires reconstitution before use. Studies reporting the highest rates of injection-site adverse findings tend to be those using sub-optimal reconstitution protocols, including incorrect pH, excessive agitation, or inappropriate concentration ranges.
Proper reconstitution using bacteriostatic water at the manufacturer-recommended concentration, gentle mixing (no vortexing), and cold-chain storage of reconstituted peptide minimizes physicochemical degradation that can contribute to aggregation-related tolerability findings. Researchers should filter reconstituted peptide through a 0.22 micron filter before use in injection studies.
Frequently Asked Questions
What adverse effects have been observed in CJC-1295 with DAC animal studies?
The most consistently reported findings are transient injection-site reactions (erythema, mild induration) resolving within 72 hours, and at supratherapeutic doses in rodents, mild reversible organomegaly. No dose-limiting toxicity, lethality, or significant hematological or hepatic abnormalities have been reported in published preclinical studies at pharmacologically relevant doses.
How long does CJC-1295 with DAC remain active in rodent plasma?
In rat pharmacokinetic studies, CJC-1295 with DAC maintains measurable plasma concentrations for approximately 6-14 days following a single subcutaneous dose, with a half-life estimated at 6-8 days depending on the dose and model. This extended half-life results from covalent albumin binding via the DAC modification.
Is CJC-1295 with DAC immunogenic in animal models?
Low-titer anti-peptide antibodies have been detected in a minority of rats in one repeat-dose study at the highest dose tested. No systemic hypersensitivity, anaphylaxis, or immune-complex deposition has been reported in published preclinical immunogenicity assessments. The DAC moiety introduces theoretical hapten potential via albumin conjugation, but clinically meaningful immunogenicity has not been demonstrated preclinically.
What dose range is typically used in CJC-1295 with DAC safety studies in rats?
Most published rodent safety studies have used subcutaneous doses between 30 and 500 mcg/kg. Pharmacologically active doses producing consistent IGF-1 elevation are in the 100-300 mcg/kg range for rats. Supratherapeutic effects (such as mild organomegaly) have been noted at 300+ mcg/kg in long-duration studies.
What washout period should researchers use after CJC-1295 with DAC dosing?
Given the extended half-life, a minimum washout of 3-4 weeks is recommended in rodent studies before crossover designs or terminal recovery assessments, based on available pharmacokinetic data showing substantial plasma concentrations for up to two weeks post-dose. Recovery groups in longer studies should include a minimum 28-day washout period.
Does CJC-1295 with DAC affect liver or kidney markers in animal models?
Available repeat-dose rat studies have not found dose-dependent elevation of hepatic enzymes (ALT, AST, ALP) or renal markers (BUN, creatinine) at pharmacologically relevant doses. These findings held in both lean and metabolically compromised animal models.
How does the DAC modification affect CJC-1295 tolerability compared to the non-DAC version?
The primary tolerability difference relates to the extended exposure duration. CJC-1295 with DAC produces sustained IGF-1 elevation over 7-14 days per dose, creating a longer window for cumulative hormonal effects that non-DAC formulations do not. Injection-site reactions appear slightly more common with the DAC form, potentially related to the albumin-binding linker. The non-DAC form clears within hours, meaning its adverse effect profile, if any, is more time-limited per dose.
Peer-Reviewed Citations
- Jetzer MR, et al. "Growth hormone-releasing factor analogs: pharmacokinetics and pharmacodynamics in animal models." J Endocrinol. 2006;189(2):327-335.
- Prakash A, Goa KL. "Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency." BioDrugs. 1999;12(2):139-157.
- Ionescu M, Frohman LA. "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog." J Clin Endocrinol Metab. 2006;91(12):4792-4797.
- Alba M, et al. "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse." Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294.
- Teichman SL, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." J Clin Endocrinol Metab. 2006;91(3):799-805.
- Veldhuis JD, Bowers CY. "Graded GH-releasing hormone stimulation of GH secretion in old men." Am J Physiol Regul Integr Comp Physiol. 2003;285(4):R795-R805.
- Sackmann-Sala L, et al. "Insulin-like growth factor-1-induced hypoglycemia precedes growth-hormone-induced hyperglycemia in mice." Endocrinology. 2009;150(9):4185-4192.
- Firth SM, Baxter RC. "Cellular actions of the insulin-like growth factor binding proteins." Endocr Rev. 2002;23(6):824-854.
DISCLAIMER: This article is for educational and scientific research reference purposes only. All compounds discussed are not approved by the FDA for use in humans or animals. All data discussed here reflects preclinical animal research or laboratory use. Palmetto Peptides sells these compounds exclusively for in vitro and preclinical laboratory research. Nothing in this article constitutes medical advice.